Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ȩ > ½ÃÀåÁ¶»ç º¸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > ÀǾàǰ ±ÔÁ¦È¯°æ
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4512)
°¨¿°Áúȯ (322)
°ñÁúȯ Ä¡·á (48)
´ç´¢º´ (164)
¹é½Å (169)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (49)
ºñó¹æ ÀǾàǰ (149)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (179)
½Å¾à°³¹ß (1306)
¾ÏÄ¡·á (856)
¾à¹°Àü´Þ (179)
ÀǾàǰ ±ÔÁ¦È¯°æ (105)
Á¤½ÅÁúȯ (88)
Á¦³×¸¯ ÀǾàǰ (116)
Á¦¾àȸ»çºÐ¼® (488)
󹿾à (128)
Áö¿ªº°°Ë»ö
ÃâÆÇ»ç¿¡¼­ ã±â

ÀǾàǰ ±ÔÁ¦È¯°æ ½ÃÀåÁ¶»çº¸°í¼­

ÀǾàǰ ±ÔÁ¦È¯°æ ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå ±Ô¸ð, »ê¾÷ ºÐ¼®, ÇâÈÄ ½ÃÀå ¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
º¸°í¼­¿¡ µû¶ó¼­ ÁÖ¿ä ±â¾÷ ºÐ¼®, °æÀïȯ°æ ºÐ¼®, ¿¬±¸°³¹ß ÇöȲ, ¿µ¾÷ Àü·«, ±â¾÷ Á¦ÈÞ ÇöȲÀ» Æ÷ÇÔÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.

»ó¼¼ºÐ·ù
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 105 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
The Pharmaceutical Market: UK
»ùÇÃ
»óǰÄÚµå :221030
¿µ±¹ÀÇ ÀǾàǰ(Pharmaceutical) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇϰí, ¿µ±¹ÀÇ °æÁ¦, Àα¸Åë°è, ÀÇ·áºñ, ÀÇ·á Á¾»çÀÚ µî¿¡ ´ëÇÑ 5°³³â ¿¹Ãø, OTC ÀǾàǰ, Á¦³×¸¯ ÀǾàǰ, »ý¹°Á¦Á¦, ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,085
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Espicom Business Intelligence
ÆäÀÌÁö¼ö Pages: 64
The Pharmaceutical Market: South Korea
»ùÇÃ
»óǰÄÚµå :97246
Çѱ¹ÀÇ ÀǾàǰ ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, ÇâÈÄ 5³â°£ ½ÃÀå ¿¹Ãø ¹× ¼öÃâÀÔ µîÀÇ Åë°è µ¥ÀÌÅÍ¿Í ÇÔ²² ÇâÈÄÀÇ ½ÃÀå Àü¸Á, ±ÔÁ¦ µ¿ÇâÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,085
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Espicom Business Intelligence
ÆäÀÌÁö¼ö Pages: 64
Healthcare Reform in China
»ùÇÃ
»óǰÄÚµå :228146
Áß±¹ÀÇ Àα¸ °èÃþ, Àüü ÀÇ·á ÀÎÇÁ¶ó ¹× ÀÇ·á °³Çõ ¿ä±¸ °³¿ä¸¦ Á¶»çÇϰí, ÀÇ·á °³Çõ(Healthcare Reform) °èȹ¿¡ ´ëÇÑ ÀǾàǰ Á¦Á¶¾÷ü, ÀÌ¿ëÀÚ, ÀÇ·á Á¾»çÀÚ °¢°¢ÀÇ °ßÇØ Á¦°ø, °³Çõ ³»¿ë ¹× ÀÌÇØ°ü°èÀÚ¿¡ ´ëÇÑ ÀÇÀÇ Æò°¡¿Í ºÐ¼®, Áß±¹ º´¿ø ¸Å´ÏÀú 23¸íÀÇ ÄÚ¸àÆ® µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,835
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Business Insights
ÆäÀÌÁö¼ö Pages: 112
China Healthcare Reform and Its Impact on IVD, Medical Device and Pharmaceutical Markets
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :221330
Áß±¹ÀÇ ÀÇ·áÁ¦µµ °³¿ä¿Í Á¦µµ °³ÇõÀÇ ¹è°æ, ü¿ÜÁø´Ü(IVD) Á¦Ç°, ÀÇ·á±â±â(Medical Device), ÀǾàǰ(Pharmaceutical) ½ÃÀåÀÇ µ¿Çâ, Áö¿ªº° ºÐ¼®À» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Kalorama Information
ÆäÀÌÁö¼ö 167 Pages
Successful Strategies for Pharmaceutical Reformulation
»ùÇÃ
»óǰÄÚµå :228143
¼ö¸íÁÖ±âÀÇ Áß°£¿¡ À§Ä¡ÇÑ ÀǾàǰÀÇ ¸ÅÃâ È®º¸¸¦ À§ÇÑ ´Ù¾çÇÑ Á¦Çüº¯°æ ¹æ¹ýÀ» Æò°¡Çϰí, °æÆó, ÁÖ»ç, °æ±¸, °æÇÇ Á¦Çüº¯°æ Àü·«¿¡ °üÇÑ °¢ Á¦¾à ±â¾÷ÀÇ »ç·Ê ¿¬±¸ ¹× ÁÖ¿ä ±â¼ú °³¿ä Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,835
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Business Insights
ÆäÀÌÁö¼ö Pages: 92
Healthcare & Pharmaceuticals in Latin America A guide to the markets and regulations
»ùÇÃ
»óǰÄÚµå :214049
¶óƾ¾Æ¸Þ¸®Ä« 19°³±¹ÀÇ ÀÇ·áÁ¦µµ °³¿ä, °¢±¹ÀÇ ÀǾàǰ ½ÃÀå, ±ÔÁ¦ °³¿ä, ±¹³» ½ÃÀå¿¡¼­ÀÇ Á¦³×¸¯ ÀǾàǰÀÇ ¿ªÇÒ µîÀ» ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,345
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç Urch Publishing, Ltd.
ÆäÀÌÁö¼ö 90 Pages
Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism
»ùÇÃ
»óǰÄÚµå :212666
½ÉÇ÷°üÁúȯ(¼øÈ¯±âÁúȯ : CVD)ÀÇ ÀÓ»ó½ÃÇè µ¿Çâ¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ÀÓ»ó½ÃÇèÀÇ °³¿ä, ÇÇÇèÀÚ ¸ðÁý °³¿ä, ÁÖ¿ä ÀûÀÀº° µ¿Çâ, ºê¶óÁú, Áß±¹, ÀεµÀÇ µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 98
Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
»ùÇÃ
»óǰÄÚµå :212665
2000-2009³â¿¡ °³½ÃµÈ Àüü ÁßÃ߽Űæ°èÁúȯ(Central Nervous System Disorders) ÀÓ»ó½ÃÇèÀ» ºÐ¼®Çϰí, ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, °£Áú, Á¤½ÅºÐ¿­Áõ, ¿ì¿ïÁõ µî ÁÖ¿ä 5°³ ÀûÀÀ¿¡ ´ëÇÑ °¢°¢ÀÇ ÀÓ»ó½ÃÇè µ¿Çâ, ºê¶óÁú, Àεµ, Áß±¹ÀÇ µ¿Çâ, Æò±Õ ÇÇÇèÀÚ¼ö µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 97
Clinical Trial Recruitment in Autoimmune Disorders-Average Patient Recruitment Per Trial has Continued to Decline Over the Past Decade
»ùÇÃ
»óǰÄÚµå :212664
ÀÚ±â¸é¿ªÁúȯ(Autoimmune Disorders)À» À§ÇÑ ÀÓ»ó½ÃÇè µ¿ÇâÀ» Á¶»ç ºÐ¼®Çϰí, ÀÓ»ó½ÃÇè °³¿ä, ÇÇÇèÀÚ ¸ðÁý °³¿ä, ÀÚ±â¸é¿ªÁúȯÀÇ ÁÖ¿ä 5°³ ÀûÀÀº° µ¿Çâ, ºê¶óÁú, Áß±¹, ÀεµÀÇ µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 09¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 95
»ùÇÃ
»óǰÄÚµå :207072
»ç¿ìµð¾Æ¶óºñ¾ÆÀÇ ÇコÄɾî(Healthcare) °ü·Ã ½ÃÀå Ãֽе¿ÇâÀ» ºÐ¼®Çϰí, ÀüüÀûÀÎ Áúº´ ¹ß»ý »óȲ, °¢ ½ÃÀå(º´¿ø ¼­ºñ½º, ÀǾàǰ, ÀÇ·á±â±¸) ÇöȲ°ú ½ÃÀå ¼ºÀå ¿¹Ãø(2011-2013³â), °¢Á¾ ¼ºÀå ¾ïÁ¦¿äÀΰú ±ÔÁ¦Àû ¹®Á¦, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,000
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç RNCOS E-Services Pvt. Ltd.
ÆäÀÌÁö¼ö 70 Pages
Booming Clinical Trials Market in India
»ùÇÃ
»óǰÄÚµå :207172
Àεµ ÀÓ»ó½ÃÇè ½ÃÀå Ãֽе¿Çâ ¿¡ ´ëÇØ Á¶»çÇØ, ÀÓ»ó½ÃÇè °Ç¼ö º¯µ¿, ¼ºÀå ÃËÁø¿äÀÎ, Àα¸ ±Ô¸ð¿Í ȯÀÚ Á¦°ø, ÀÎÇÁ¶ó¡¤ÀÎÀç »óȲ, ºñ¿ë ºÐ¼®, ±ÔÁ¦ ȯ°æ, ÁÖ¿ä ±â¾÷ °³¿äµîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,000
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç RNCOS E-Services Pvt. Ltd.
ÆäÀÌÁö¼ö 145 Pages
Private Healthcare Market in Poland 2011: Development forecasts for 2011-2013
»ùÇÃ
»óǰÄÚµå :207777
Æú¶õµåÀÇ ¹Î°£ÀÇ·á(Private Healthcare) ½ÃÀå¿¡ ´ëÇØ Æ÷°ýÀûÀ¸·Î ºÐ¼®Çϰí, ¹Î°£ÀǷẸÇè ½ÃÀå, ¹Î°£ÀÇ·á½Ã¼³ µ¿Çâ, 2011-2013³â ¹ßÀü ¿¹Ãø, ¹ý±ÔÁ¦ µ¿Çâ, ½ÃÀå ÁøÃâ ±â°ü µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,562
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç PMR
ÆäÀÌÁö¼ö 233 Pages
Private Healthcare Market in Central Europe 2011: Development forecasts for 2011-2013
»ùÇÃ
»óǰÄÚµå :207776
Áß¾ÓÀ¯·´(üÄÚ, ½½·Î¹ÙŰ¾Æ, Çë°¡¸®, Æú¶õµå, ·ç¸¶´Ï¾Æ, ºÒ°¡¸®¾Æ)ÀÇ ¹Î°£ÀÇ·á(Private Healthcare) ½ÃÀå¿¡ ´ëÇØ Æ÷°ýÀûÀ¸·Î ºÐ¼®Çϰí, ¹Î°£ÀǷẸÇè ½ÃÀå, ¹Î°£ ÀÇ·á½Ã¼³ÀÇ Ãֽе¿Çâ, 2011-2013³â ¹ßÀü ¿¹Ãø, ¹ý±ÔÁ¦ µ¿Çâ, ½ÃÀå ÁøÃâ ±â°üÀÇ µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,558
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç PMR
ÆäÀÌÁö¼ö 252 Pages
South Korea: Healthcare System and Drug Regulatory Overview
»ùÇÃ
»óǰÄÚµå :208260
Çѱ¹ÀÇ ÀÇ·áºñ, ¹ý±ÔÁ¦, ¾à°¡ ¹× »óȯ µ¿Çâ, ÃÖ±ÙÀÇ ÀÇ·á °³ÇõÀ» Æ÷ÇÔÇÑ ÀÇ·áÁ¦µµÀÇ °³¿ä µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,900
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 45
Mexico: Pharmaceutical Industry Infrastructure Overview
»ùÇÃ
»óǰÄÚµå :206512
¸ß½ÃÄÚÀÇ ÀǾàǰ(Pharmaceutical) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ¸ß½ÃÄÚ ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇÏ´Â Á¤ºÎÀÇ Áö¿ø Á¦µµ, ´ëÇü Á¦¾àȸ»ç 10»çÀÇ ºñÁö´Ï½º È®´ë µ¿Ç⠵ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,900
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 43
Mexico: Healthcare System and Drug Regulatory Overview
»ùÇÃ
»óǰÄÚµå :206511
¸ß½ÃÄÚÀÇ ÀÇ·áºñ, ¹ý±ÔÁ¦»ó °úÁ¦, ¾à°¡¿Í »óȯ µ¿Çâ, ÀǷẸÇè Á¦µµÀÇ °³¿ä, ÁöÀûÀç»ê ¹®Á¦ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,900
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 36
Turkey: Healthcare System and Drug Regulatory Overview
»ùÇÃ
»óǰÄÚµå :206531
ÅÍŰÀÇ ÀÇ·áºñ, ¹ý±ÔÁ¦, ¾à°¡ ¹× »óȯ Á¦µµ, ÀǷẸÇè°ú ÀÇ·áÁ¦µµ, ÁöÀûÀç»ê ¹®Á¦ µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,900
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 36
Emerging Market for Clinical Trials in Russia - Curbs on New Drug Approval Timelines and Registration Fees Encourage the Emergence of a Major Global Player
»ùÇÃ
»óǰÄÚµå :203104
·¯½Ã¾ÆÀÇ ÀÓ»ó½ÃÇè(Clinical Trials) ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, ÀÓ»ó½ÃÇè µ¿Çâ, ·¯½Ã¾Æ ½ÃÀå ȯ°æÀÇ Æ¯¼º, ±ÔÁ¦ ȯ°æ ¹× ÀÓ»ó½ÃÇè ¼öʱâ°ü(CRO) °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 89
Emerging Market for Clinical Trials in Argentina - Major Cost Advantages over the US in Conducting Clinical Trials Will Encourage Drug Development
»ùÇÃ
»óǰÄÚµå :203103
¾Æ¸£ÇîÆ¼³ªÀÇ ÀÓ»ó½ÃÇè(Clinical Trials) ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, ÀÓ»ó½ÃÇè °³¿ä ¹× µ¿Çâ, ¶óƾ¾Æ¸Þ¸®Ä« ±¹°¡ÀÇ ÀÓ»ó½ÃÇè °Ç¼ö ºñ±³, ¾Æ¸£ÇîÆ¼³ª ½ÃÀåÀÇ Æ¯¼º ¹× ±ÔÁ¦ ȯ°æ, ÀÓ»ó½ÃÇè ¼öʱâ°ü(CRO) °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 86
The Pharmaceutical Market: Serbia
»ùÇÃ
»óǰÄÚµå :181336
¼¼¸£ºñ¾ÆÀÇ ÀǾàǰ(Pharmaceutical) ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, ¼¼¸£ºñ¾ÆÀÇ ÀÇ·áÁ¦µµ, ÀÎÇÁ¶ó µ¿Çâ, ¾à°¡ ¼³Á¤°ú »óȯ µ¿Çâ, ½ÃÀå µ¿Çâ°ú °æÀï, ÇâÈÄÀÇ ±âȸ¿Í °úÁ¦ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,085
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Espicom Business Intelligence
ÆäÀÌÁö¼ö 44 Pages
The Pharmaceutical Market: Slovakia
»ùÇÃ
»óǰÄÚµå :181335
½½·Î¹ÙŰ¾ÆÀÇ ÀǾàǰ(Pharmaceutical) ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, ½½·Î¹ÙŰ¾ÆÀÇ ÀÇ·áÁ¦µµ, ÀÎÇÁ¶ó µ¿Çâ, ¾à°¡ ¼³Á¤°ú »óȯ µ¿Çâ, ½ÃÀå µ¿Çâ°ú °æÀï, ÇâÈÄÀÇ ±âȸ¿Í °úÁ¦ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,085
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Espicom Business Intelligence
ÆäÀÌÁö¼ö 56 Pages
The Pharmaceutical Market: Slovenia
»ùÇÃ
»óǰÄÚµå :181334
½½·Îº£´Ï¾ÆÀÇ ÀǾàǰ(Pharmaceutical) ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, ½½·Îº£´Ï¾ÆÀÇ ÀÇ·áÁ¦µµ, ÀÎÇÁ¶ó µ¿Çâ, ¾à°¡ ¼³Á¤°ú »óȯ µ¿Çâ, ½ÃÀå µ¿Çâ°ú °æÀï, ÇâÈÄÀÇ ±âȸ¿Í °úÁ¦ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,085
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Espicom Business Intelligence
ÆäÀÌÁö¼ö 50 Pages
The Pharmaceutical Market: Spain
»ùÇÃ
»óǰÄÚµå :181332
½ºÆäÀÎÀÇ ÀǾàǰ(Pharmaceutical) ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, ½ºÆäÀÎÀÇ ÀÇ·áÁ¦µµ, ÀÎÇÁ¶ó µ¿Çâ, ¾à°¡ ¼³Á¤°ú »óȯ µ¿Çâ, ½ÃÀå µ¿Çâ°ú °æÀï, ÇâÈÄÀÇ ±âȸ¿Í °úÁ¦ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,085
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Espicom Business Intelligence
ÆäÀÌÁö¼ö 106 Pages
Turkey: Pharmaceutical Industry Infrastructure Overview
»ùÇÃ
»óǰÄÚµå :206532
ÅÍŰÀÇ ÀǾàǰ(Pharmaceutical) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, ÅÍŰ¿¡¼­ÀÇ ¿¬±¸°³¹ß ¹× Á¦Á¶ µ¿Çâ, ÅÍŰ ´ëÇü Á¦¾àȸ»ç¿Í ±× ÀÎÇÁ¶ó, ÇöÀçÀÇ Àü·«, ¾Æ¿ô¼Ò½Ì ¹× À¯Åë µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,900
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Datamonitor
ÆäÀÌÁö¼ö Pages: 60
Statistical Overview of Healthcare in Selected European Countries
»ùÇÃ
»óǰÄÚµå :201016
À¯·´ ÁÖ¿ä ±¹°¡ÀÇ ÇコÄɾî(Healthcare) Á¦µµ¿¡ ´ëÇØ ºÐ¼®Çϰí, ÇコÄÉ¾î °ü·Ã ¹ý±Ô¿Í »óȯ Á¦µµ, ÁÖ¿ä 12°³ ±¹°¡ÀÇ ±¹³»ÃÑ»ý»ê(GDP)°ú ÇコÄÉ¾î µ¥ÀÌÅÍ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,950
¹ßÇàÀÏ 2011³â 06¿ù
¸®¼­Ä¡»ç Medtech Insight
ÆäÀÌÁö¼ö 103 pages